Free Trial
NASDAQ:ATAI

Atai Life Sciences (ATAI) Stock Price, News & Analysis

$1.49
+0.01 (+0.68%)
(As of 07/22/2024 ET)
Today's Range
$1.46
$1.52
50-Day Range
$1.27
$2.05
52-Week Range
$1.03
$2.85
Volume
319,373 shs
Average Volume
1.36 million shs
Market Capitalization
$249.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Atai Life Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
604.7% Upside
$10.50 Price Target
Short Interest
Bearish
7.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$290,502 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.13 out of 5 stars

Medical Sector

756th out of 894 stocks

Pharmaceutical Preparations Industry

354th out of 426 stocks

ATAI stock logo

About Atai Life Sciences Stock (NASDAQ:ATAI)

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

ATAI Stock Price History

ATAI Stock News Headlines

I spent 44 years on Wall Street. If you knew what I know, you’d be terrified too.
The Most Important Presentation in America Right Now "Most people won't know what to do when their savings run out... Or when the stocks in their portfolios fall by half," says Wall Street icon Louis Navellier. "It's going to affect everything about our normal way of life: Our money, the value of our homes, our ability to retire." When it makes landfall, it's impact will be more violent and more severe than any financial crisis we've ever seen…
3 Psychedelic Stocks to Ride to the Moon and Beyond
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
I spent 44 years on Wall Street. If you knew what I know, you’d be terrified too.
The Most Important Presentation in America Right Now "Most people won't know what to do when their savings run out... Or when the stocks in their portfolios fall by half," says Wall Street icon Louis Navellier. "It's going to affect everything about our normal way of life: Our money, the value of our homes, our ability to retire." When it makes landfall, it's impact will be more violent and more severe than any financial crisis we've ever seen…
atai Life Sciences bolsters board with two new directors
See More Headlines
Receive ATAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/17/2024
Today
7/22/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATAI
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.50
High Stock Price Target
$15.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+604.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-40,220,000.00
Net Margins
-12,810.51%
Pretax Margin
-11,484.11%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
$1.47 per share

Miscellaneous

Free Float
115,175,000
Market Cap
$249.44 million
Optionable
Optionable
Beta
0.80
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Christian  AngermayerMr. Christian Angermayer (Age 46)
    Founder & Chairman of the Supervisory Board
    Comp: $70k
  • Mr. Florian Brand (Age 37)
    Co-Founder, MD & CEO
    Comp: $835.44k
  • Dr. Srinivas G. Rao M.D. (Age 55)
    Ph.D., Co-Founder & Chief Scientific Officer
    Comp: $834.15k
  • Ms. Anne Johnson (Age 55)
    Chief Financial Officer
  • Dr. Michael Raven Ph.D.
    Senior Vice President of Operations
  • Mr. Frank Stegert (Age 43)
    Vice President of Investment & Venture Management
  • Mr. Ryan Barrett (Age 43)
    Senior VP, General Counsel & Corporate Secretary
  • Dr. Glenn Short Ph.D.
    Senior Vice President of Early Development
  • Dr. Sahil V. Kirpekar M.D. (Age 38)
    Chief Business Officer
  • Dr. Kevin Craig M.D.
    Senior Vice President of Clinical Development

ATAI Stock Analysis - Frequently Asked Questions

How have ATAI shares performed this year?

Atai Life Sciences' stock was trading at $1.41 at the start of the year. Since then, ATAI shares have increased by 5.7% and is now trading at $1.49.
View the best growth stocks for 2024 here
.

How were Atai Life Sciences' earnings last quarter?

Atai Life Sciences (NASDAQ:ATAI) issued its quarterly earnings data on Friday, May, 17th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.03. Atai Life Sciences had a negative trailing twelve-month return on equity of 43.21% and a negative net margin of 12,810.51%.

When did Atai Life Sciences IPO?

Atai Life Sciences (ATAI) raised $200 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.

Who are Atai Life Sciences' major shareholders?

Atai Life Sciences' top institutional shareholders include SG Americas Securities LLC (0.03%) and Wedmont Private Capital (0.01%). Insiders that own company stock include Apeiron Investment Group Ltd, Florian Brand, Srinivas Rao and Anne Nagengast Johnson.
View institutional ownership trends
.

How do I buy shares of Atai Life Sciences?

Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Atai Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB) and Twitter (TWTR).

This page (NASDAQ:ATAI) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners